Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 5/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23588291 | 0.84 | NR4A1 (0.60) | NR4A2MAOBMAOAF2PRSS1 | |
| SCHEMBL16697981 | 0.82 | NPC1 (0.56) | NR4A2MAOBMAOAF2PRSS1 | |
| SCHEMBL641475 | 0.79 | LMNA (0.50) | ALDH1A1MAPT | |
| SCHEMBL10991891 | 0.79 | MAOB (0.80) | NR4A2MAOBMAOAAPPNPC1 | |
| SCHEMBL12522020 | 0.77 | MAOB (0.61) | NR4A2MAOBMAOAAPPNPC1 | |
| SCHEMBL3624903 | 0.76 | MAOB (0.69) | NR4A2MAOBMAOAAPPNPC1 | |
| SCHEMBL11600066 | 0.76 | MAOB (0.69) | NR4A2MAOBMAOAAPPNPC1 | |
| SCHEMBL1369316 | 0.76 | NR4A2 (1.00) | NR4A2MAOBMAOANPC1RAB9A | |
| SCHEMBL11218725 | 0.75 | NPC1 (0.86) | NR4A2MAOBMAOANPC1RAB9A | |
| SCHEMBL548439 | 0.74 | PRSS1 (0.60) | MAOAF2PRSS1ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | NR4A2 1048/4885MAOB 3527/4885MAOA 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.